Virax Biolabs Group LimitedNASDAQ: VRAX

LONDON , Oct. 23, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a distribution agreement with Europa Biosite to commercialize the company's ImmuneSelect Research Use portfolio in the United Kingdom and Ireland through its wholly owned subsidiary Cambridge Bioscience. "ImmuneSelect is an important suite of profiling solutions for assessing adaptive immunity and we are pleased to partner with Europa Biosite, a leader in life science distribution across Europe," said James Foster, CEO of Virax Biolabs.

LONDON , Aug. 29, 2024 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today it will be hosting a booth at the 7th European Congress of Immunology (ECI), which is taking place from September 1 - 4, 2024, in Dublin, Ireland. The Company will be showcasing its portfolio of immune profiling products for research use at Booth C13, and management will be available for discussions with research organizations and potential customers.

Virax Biolabs Group Ltd (NASDAQ: VRAX) saw its shares surge by approximately 45% on Wednesday after announcing a partnership with a leading supplier of Mpox detection kits. The partnership grants Virax the rights to sell RT-PCR tests for Mpox across more than a dozen European countries and several Middle Eastern nations.

LONDON , Aug. 28, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that it has entered into a distribution agreement with a supplier of (RT) PCR Mpox virus detection kits to commercialize them in 13 European countries as well as members of the Gulf Cooperation Council ("GCC") including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates. The RT PCR Mpox virus detection kits are CE-marked for sale in Europe and also authorized by the Medicines and Healthcare products Regulatory Agency (MHRA), the product regulatory agency for the United Kingdom.

LONDON , Aug. 23, 2024 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced the closing of its previously announced registered direct offering for the purchase and sale of an aggregate of 1,108,892 of its ordinary shares at a purchase price of $4.50 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

Virax Biolabs (NASDAQ: VRAX ) stock is rocketing higher on Thursday morning alongside heavy pre-market trading of the biotechnology company's shares. The heavy trading of Virax Biolabs stock has more than 15.2 million shares trading hands as of this writing.